Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
TGF-beta Antibody Uptake in Recurrent High-Grade Glioma Imaged with Zr-89-Fresolimumab PET
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.115.154401
Transforming growth factor-beta (TGF-beta) signaling is involved in glioma development. The monoclonal antibody fresolimumab (GC1008) can neutralize all mammalian isoforms of TGF-beta, and tumor uptake can be visualized and quantified with Zr-89-fresolimumab PET in mice. The aim of this study was to investigate the fresolimumab uptake in recurrent high-grade gliomas using Zr-89-fresolimumab PET and to assess treatment outcome in patients with recurrent high-grade glioma treated with fresolimumab. Methods: Patients with recurrent glioma were eligible. After intravenous administration of 37 MBq (5 mg) of Zr-89-fresolimumab, PET scans were acquired...
Martha W. den Hollander, Frederike Bensch, Andor W. J. M. Glaudemans, Thijs H Oude Munnink, Roelien H. Enting, Wilfred F. A. den Dunnen, Mart A. A. M. Heesters, Frank A. E. Kruyt, Marjolijn N. Lub-de Hooge, Jan Cees de Groot, Joseph Pearlberg, Jourik A. Gietema, Elisabeth G. E. de Vries, Annemiek M. E. Walenkamp
18F-FDG-PET-CT assessed subclinical arterial inflammation is positively associated with non-invasive markers of arterial stiffness in recently diagnosed type 2 diabetes patients
S. A. De Boer, Marieke C Hovinga-de Boer, J. D. Lefrandt, A. M. Van Roon, P. W. Kamphuisen, H. L. Lutgers, A. W. J. M. Glaudemans, H. J. Lambers Heersprink, R. H. J. Slart, D. J. Mulder
Nuclear Medicine and Radiologic Imaging in Sports Injuries
18F-FDOPA Accumulation in Traumatic Rib Fractures: A Potential Pitfall
Published in: Clinical Nuclear Medicine
Access to document
10.1097/RLU.0000000000000761
F-FDOPA (6-[F]fluoro-L-DOPA) is used for the detection and staging of neuroendocrine tumors by visualizing the uptake of amine precursors in these tumors with high sensitivity and specificity. However, as this tracer is only available in a limited number of centers worldwide and the minority of the nuclear medicine specialists and referring clinicians is familiar with the distribution pattern of F-FDOPA, some physiological uptake patterns and pitfalls remain to be fully elucidated. Here, we present 2 cases of markedly increased uptake in the ribs after traumatic injury.
Gilles N. Stormezand, Andor W. J. M. Glaudemans, Riemer H. J. A. Slart
Challenges in diagnosing infection in the diabetic foot
Published in: Diabetic Medicine
Access to document
10.1111/dme.12750
Diagnosing the presence of infection in the foot of a patient with diabetes can sometimes be a difficult task. Because open wounds are always colonized with microorganisms, most agree that infection should be diagnosed by the presence of systemic or local signs of inflammation. Determining whether or not infection is present in bone can be especially difficult. Diagnosis begins with a history and physical examination in which both classic and secondary’ findings suggesting invasion of microorganisms or a host response are sought. Serological tests may be helpful, especially...
A. W. J. M. Glaudemans, I. Uckay, B. A. Lipsky